Skip to main content
SpringerLink
Log in

Endocrine therapy in metastatic breast cancer

  • Chapter
Biological and Hormonal Therapies of Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 94))

Abstract

Breast cancer is the most common cancer diagnosis and the second leading cancer-related cause of death in American women. In 1996, it is estimated that there will be 185,700 new diagnoses of and 44,560 deaths due to breast cancer [1]. At diagnosis, approximately 5% of women have metastatic disease. Unfortunately, treatment of advanced disease is currently only palliative.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Parker SL, Tong T, Bolden S, Wingo PA. 1996. Cancer Statistics, 1996. CA 65:5–27.

    Google Scholar 

  2. Taylor SG, Gelman RS, Falkson G, Cummings H. 1986. Combination chemotherapy corn-pared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Intern Med 104:455–461.

    PubMed  Google Scholar 

  3. Anonymous. 1986. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia. J Clin Oncol 4:186–193.

    Google Scholar 

  4. Muss HB. 1992. Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res Treat 21:15–26.

    PubMed  CAS  Google Scholar 

  5. Kimmick G, Muss HB, 1995. Current status of endocrine therapy for metastatic breast cancer. Contemp Oncol 9:877–890.

    CAS  Google Scholar 

  6. Beatson GT. 1896. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 2:104–107.

    Google Scholar 

  7. Davidson NE. 1994. Ovarian ablation as treatment for young women with breast cancer (review). Monogr Nat cancer Inst ••:95–99.

    Google Scholar 

  8. Santen RJ, Manni A, Harvey H, Redmond C. 1990. Endocrine treatment of breast cancer in women (review). Endocrine Rev 11:221–265.

    CAS  Google Scholar 

  9. Dowsett M. 1990. Novel approaches to the endocrine therapy of breast cancer (review). Eur J Cancer 26:989–992.

    PubMed  CAS  Google Scholar 

  10. Cash R, Brough AJ, Cohen MN, Satoh PS. 1967. Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial. J Clin Endocrinol Metab 27:1239–1248.

    PubMed  CAS  Google Scholar 

  11. Griffiths CT, Hall TC, Saba Z, Barlow JJ, Nevinny HB. 1973. Preliminary trial of aminoglutethimide in breast cancer. Cancer 32:31–37.

    PubMed  CAS  Google Scholar 

  12. Nemoto T, Patel J, Rosner D, Dao TL. 1984. Tamoxifen (Nolvadex) versus adrenalectomy in metastatic breast cancer. Cancer 53:1333–1335.

    PubMed  CAS  Google Scholar 

  13. Santen RJ, Worgul TJ, Samojlik E, Interrante A, Boucher AE, Lipton A, Harvey HA, White DS, Smart E, Cox C, Wells SA. 1981. A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med 305:545–551.

    PubMed  CAS  Google Scholar 

  14. Kiang DT, Frenning DH, Vosika GJ, Kennedy BJ. 1980. Comparison of tamoxifen and hypophysectomy in breast cancer treatment. Cancer 45:1322–1325.

    PubMed  CAS  Google Scholar 

  15. Harvey HA, Santen RJ, Osterman J, Samojlik E, White DS, Lipton A. 1979. A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer. Cancer 43:2207–2214.

    PubMed  CAS  Google Scholar 

  16. Miller WR. 1990. Endocrine treatment for breast cancers: biological rationale and current progress. J Steroid Biochem Mol Biol 37:467–480.

    PubMed  CAS  Google Scholar 

  17. Sutherland DJ, Mobbs BG. 1992. Hormones and cancer. In Tannock IF, Hill RP, eds. The Basic Science of Oncology, 2nd ed. New York: McGraw-Hill, Health Professions Division, pp. 207–232.

    Google Scholar 

  18. Lippman ME. 1988. Steroid hormone receptors and mechanisms of growth regulation of human breast cancer. In Lippman ME, Lichtner AS, Danforth DN, eds. Diagnosis and Management of Breast Cancer. Philadelphia: W.B. Saunders, pp. 327–347.

    Google Scholar 

  19. Editorial. 1960. Androgens and estrogens in the treatment of disseminated mammary carcinoma. Retrospective study of nine hundred forty-four patients. Report of the Council on Drugs. JAMA 172:135–147.

    Google Scholar 

  20. Carter AC, Sedransk N, Kelley RM, Ansfield FJ, Ravdin RG, Talley RW, Potter NR. 1977. Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group. JAMA 237:2079–2080.

    PubMed  CAS  Google Scholar 

  21. Pritchard KI, Sutherland DJA. 1989. Diagnosis and therapy of breast cancer: the use of endocrine therapy. Hematol Oncol Clin North Am 3:765–805.

    PubMed  CAS  Google Scholar 

  22. Minton MJ, Knight RK, Rubens RD, Hayward JL. 1981. Corticosteroids for elderly patients with breast cancer. Cancer 48:883–887.

    PubMed  CAS  Google Scholar 

  23. Bruera E, Roca E, Cedaro L, Carraro S, Chacon R. 1985. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 69:751–754.

    PubMed  CAS  Google Scholar 

  24. Lippman M, Bolan G, Huff K. 1976. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36:4595–4601.

    PubMed  CAS  Google Scholar 

  25. Wakeling AE. 1993. The future of new pure antiestrogens in clinical breast cancer (review). Breast Cancer Res Treat 25:1–9.

    PubMed  CAS  Google Scholar 

  26. Litherland S, Jackson IM. 1988. Antioestrogens in the management of hormone-dependent cancer. Cancer Treat Rev 15:183–194.

    PubMed  CAS  Google Scholar 

  27. Manni A. 1987. Tamoxifen therapy of metastatic breast cancer. J Lab Clin Med 109:290–299.

    PubMed  CAS  Google Scholar 

  28. Henderson IC. 1991. Endocrine therapy of metastatic breast cancer. In Harris JR, Hellman S, Henderson IC, Kinne DW, eds. Breast Diseases, 2nd ed. New York: Lippincott, pp. 559–603.

    Google Scholar 

  29. Canney PA, Griffiths T, Latief TN, Priestman TJ. 1987. Clinical significance of tamoxifen withdrawal response (letter). Lancet 1:36.

    PubMed  CAS  Google Scholar 

  30. Buckley MM, Goa KL. 1989. Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use (review). Drugs 37:451–490.

    PubMed  CAS  Google Scholar 

  31. Malet C, Gompel A, Spritzer P, Bricout N, Yaneva H, Mowszowicz I, Mauvais-Jarvis P. 1988. Tamoxifen and hydroxytamoxifen isomers versus estradiol effects on normal human breast cells in culture. Cancer Res 48:7193–7199.

    PubMed  CAS  Google Scholar 

  32. Karnik PS, Kulkarni S, Liu XP, Budd GT, Bukowski RM. 1994. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res 54:349–353.

    PubMed  CAS  Google Scholar 

  33. Katzenellenbogen BS. 1991. Antiestrogen resistance: mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy (editorial; comment). J Natl Cancer Inst 83:1434–1435.

    PubMed  CAS  Google Scholar 

  34. Paik S, Hartmann DP, Dickson RB, Lippman ME. 1994. Antiestrogen resistance in ER positive breast cancer cells (review). Breast Cancer Res Treat 31:301–307.

    PubMed  CAS  Google Scholar 

  35. Mauvais-Javis P, Baudot N, Castaigne D, Banzet P, Kuttenn F. 1986. Trans-4Hydroxytamoxifen concentration and metabolism after local percutaneous administration to human breast. Cancer Res 46:1521–1525.

    PubMed  CAS  Google Scholar 

  36. Murphy C, Fotsis T, Pantzar P, Adlercreutz H, Martin F. 1987. Analysis of tamoxifen, Ndesmethyltamoxifen and 4-hydroxytamoxifen levels in cytosol and KC1-nuclear extracts of breast tumours from tamoxifen treated patients by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM). J Steroid Biochem 28:609–618.

    PubMed  CAS  Google Scholar 

  37. Osborne CK, Wiebe VJ. McGuire WL, Ciocca DR, DeGregorio MW. 1992. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J Clin Oncol 10:304–310.

    PubMed  CAS  Google Scholar 

  38. Wiebe VJ, Osborne CK, McGuire WL, DeGregorio MW. 1992. Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors. J Clin Oncol 10:990–994.

    PubMed  CAS  Google Scholar 

  39. Wolf DM, Langan-Fahey SM, Parker CJ, McCague R, Jordan VC. 1993. Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites. J Natl cancer Inst 85:806–812.

    PubMed  CAS  Google Scholar 

  40. Clarysse A. 1985. Hormone-induced tumor flare (editorial). Eur J Cancer Clin Oncol 21:545–547.

    PubMed  CAS  Google Scholar 

  41. Plotkin D, Lechner JJ, Jung WE, Rosen PJ. 1978. Tamoxifen flare in advanced breast cancer. JAMA 240:2644–2646.

    PubMed  CAS  Google Scholar 

  42. Rose DP, Fischer AH, Jordan VC, 1981. Activity of the antioestrogen trioxifene against NNitrosomethylurea-induced rat mammry carcinomas. Eur J Cancer Clin Oncol 17:893–898.

    PubMed  CAS  Google Scholar 

  43. Witte RS, Pruitt B, Tormey DC, Moss S, Rose DP, Falkson G, Carbone PP, Ramirez G, Falkson H, Pretorius FJ. 1986. A phase I/II investigation of trioxifene mesylate in advanced breast cancer. Clinical and endocrinologie effects. Cancer 57:34–39.

    PubMed  CAS  Google Scholar 

  44. Lee RW, Buzdar AU, Blumenschein GR, Hortobagyi GN. 1986. Trioxifene mesylate in the treatment of advanced breast cancer. Cancer 57:40–43.

    PubMed  CAS  Google Scholar 

  45. Anttila M, Valavaara R, Kivinen S, Maenpaa J. 1990. Pharmacokinetics of toremifene. J Steroid Biochem 36:249–252.

    PubMed  CAS  Google Scholar 

  46. Kangas L. 1990. Introduction to toremifene (review). Breast Cancer Res Treat 16 (Suppl):S3–S7.

    PubMed  Google Scholar 

  47. Valavaara R. 1990. Phase II trials with toremifene in advanced breast cancer: a review. Breast Cancer Res Treat 16 (Suppl):S31–S35.

    PubMed  Google Scholar 

  48. Stenbygaard LE, Herrstedt J, Thomsen JF, Svendsen KR, Engelholm SA. 1993. Toremifene and tamoxifen in advanced breast cancer - a double-blind cross-over trial. Breast Cancer Res Treat 25:57–63.

    PubMed  CAS  Google Scholar 

  49. Vogel CL, Shemano I, Schoenfelder J, Gams RA, Green MR. 1993. Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J Clin Oncol 11:345–350.

    PubMed  CAS  Google Scholar 

  50. Kawamura I, Mizota T, Lacey E, Tanaka Y, Manda T, Shimomura K, Kohsaka M. 1993. The estrogenic and antiestrogenic activities of droloxifene in human breast cancers. Jpn J Pharmacol 63:27–34.

    PubMed  CAS  Google Scholar 

  51. Buzdar AU, Kau S, Hortobagyi GN, Theriault RL, Booser D, Holmes FA, Walters R, Krakoff IH. 1994. Phase I trial of droloxifene in patients with metastatic breast cancer. Cancer Chemother Pharmacol 33:313–316.

    PubMed  CAS  Google Scholar 

  52. Bruning PF. 1992. Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: preliminary results of a double-blind dose-finding phase II trial. Eur J Cancer 28A:1404–1407.

    PubMed  CAS  Google Scholar 

  53. Deschenes L. 1991. Droloxifene, a new antiestrogen, in advanced breast cancer. A double-blind dose-finding study. The Droloxifene 002 International Study Group. Am J Clin Oncol 14 (Suppl 2):S52–S55.

    PubMed  Google Scholar 

  54. Bellmunt J, Sole L. 1991. European early phase II dose-finding study of droloxifene in advanced breast cancer. Am J Clin Oncol 14 (Suppl 2):S36–S39.

    PubMed  Google Scholar 

  55. Haarstad H, Gundersen S, Wist E, Raabe N, Mella O, Kvinnsland S. 1992. Droloxifene - a new anti-estrogen. A phase II study in advanced breast cancer. Acta Oncol 31:425–428.

    PubMed  CAS  Google Scholar 

  56. Stein RC, Dowsett M, Cunningham DC, Davenport J, Ford HT, Gazet JC, Coombes RC. 1990. Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study. Br J Cancer 61:451–453.

    PubMed  CAS  Google Scholar 

  57. Coombes RC, Jarman M, Dowsett M. 1993. New endocrine agents for the treatment of breast cancer. Recent Results in Cancer Res 127:267.

    CAS  Google Scholar 

  58. Wakeling AE. 1990. Therapeutic potential of pure antioestrogens in the treatment of breast cancer (review). J Steroid Biochem Mol Biol 37:771–775.

    PubMed  CAS  Google Scholar 

  59. Wakeling AE. 1990. Novel pure antiestrogens. Mode of action and therapeutic prospects. Ann NY Acad Sci 595:348–356.

    PubMed  CAS  Google Scholar 

  60. Poulin R, Merand Y, Poirier D, Levesque C, Dufour JM, Labrie F. 1989. Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164,384, a new steroidal antiestrogen, in ZR-75–1 human breast cancer cells. Breast Cancer Res Treat 14:65–76.

    PubMed  CAS  Google Scholar 

  61. Thompson EW, Katz D, Shima TB, Wakeling AE, Lippman ME, Dickson RB. 1989. ICI 164,384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness. Cancer Res 49:6929–6934.

    PubMed  CAS  Google Scholar 

  62. Bronzert DA, Davidson N, Lippman M. 1986. Estrogen and antiestrogen resistance in human breast cancer cell lines (review). Adv Exp Med Biol 196:329–345.

    PubMed  CAS  Google Scholar 

  63. Gottardis MM, Jiang SY, Jeng MH, Jordan VC. 1989. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 49:4090–4093.

    PubMed  CAS  Google Scholar 

  64. Wakeling AE, Bowler J. 1992. ICI 182,780, a new antioestrogen with clinical potential (review). J Steroid Biochem Mol Biol 43:173–177.

    PubMed  CAS  Google Scholar 

  65. Wakeling AE, Dukes M, Bowler J. 1991. A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867–3873.

    PubMed  CAS  Google Scholar 

  66. DeFriend DJ, Howell A, Nicholson RI, et al. 1994. Investigation of a new pure antiestrogen (ICI 182,780) in women with primary breast cancer. Cancer Res 54:408–414.

    Google Scholar 

  67. Howell A, DeFriend D, Robertson J, Blarney R, Walton P. 1995. Response to a specific antioestrogen (ICI 182,780) in tamoxifen-resistant breast cancer (see comments). Lancet 345:29–30.

    PubMed  CAS  Google Scholar 

  68. Bakker GH, Setyono-Han B, Portengen H, De Jong FH, Foekens JA, Klijn JG. 1990. Treatment of breast cancer with different antiprogestins: preclinical and clinical studies. J Steroid Biochem Mol Biol 37:789–794.

    PubMed  CAS  Google Scholar 

  69. Schneider MR, Michna H, Nishino Y, Neef G, el Etreby MF. 1990. Tumor-inhibiting potential of ZK 112.993, a new progesterone antagonist, in hormone-sensitive, experimental rodent and human mammary tumors. Anticancer Res 10:683–687.

    PubMed  CAS  Google Scholar 

  70. Cunningham D, Gazet J, Ford HT, Coombes RC. 1987. Oral gestrinone: a novel antiprogestin with no antitumor activity in endocrine-sensitive breast cancer. Cancer Treat Rep 71:1091–1092.

    PubMed  CAS  Google Scholar 

  71. Perrault DJ, Logan DM, Stewart DJ, Bramwell VH, Paterson AH, Eisenhauer EA. 1988. Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. Invest New Drugs 6:207–210.

    PubMed  CAS  Google Scholar 

  72. Manni A, Santen RJ. 1988. Clinical use of aromatase inhibitors in the treatment of breast cancer (review). Cancer Treat Res 39:67–81.

    PubMed  CAS  Google Scholar 

  73. Santen RJ, Worgul TJ, Lipton A, Harvey H, Boucher A, Samojlik E, Wells SA. 1982. Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. Ann Intern Med 96:94–101.

    PubMed  CAS  Google Scholar 

  74. Stuart-Harris RC, Smith IE. 1984. Aminoglutethimide in the treatment of advanced breast cancer. Cancer Treat Rev 11:189–204.

    PubMed  CAS  Google Scholar 

  75. Goss PE, Gwyn KM. 1994. Current perspectives on aromatase inhibitors in breast cancer (review). J Clin Oncol 12:2460–2470.

    PubMed  CAS  Google Scholar 

  76. Bolufer P, Ricart E, Lluch A, Vazquez C, Rodriguez A, Ruiz A, Llopis F, Garcia-Conde J, Romero R. 1992. Aromatase activity and estradiol in human breast cancer: its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging. J Clin Oncol 10:438–446.

    PubMed  CAS  Google Scholar 

  77. Lawrence BV, Lipton A, Harvey HA, Santen RJ, Wells SA Jr, Cox CE, Smart EK. 1980. Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy. Cancer 45:786–791.

    PubMed  CAS  Google Scholar 

  78. Wander HE, Blossey HC, Nagel GA. 1986. Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer. Eur J Cancer Clin Oncol 22:1371–1374.

    PubMed  CAS  Google Scholar 

  79. Brufman G, Biran S. 1990. Second line hormonal therapy with aminoglutethimide in metastatic breast cancer. Acta Oncol 29:717–720.

    PubMed  CAS  Google Scholar 

  80. Messeih AA, Lipton A, Santen RJ, Harvey HA, Boucher AE, Murray R, Ragaz J, Buzdar AU, Nagel GA, Henderson IC. 1985. Aminoglutethimide-induced hematologic toxicity: worldwide experience. Cancer Treat Rep 69:1003–1004.

    PubMed  CAS  Google Scholar 

  81. Foster AB, Jarman M, Leung CS, Rowlands MG, Taylor GN, Plevey RG. 1985. Analogues of aminoglutethimide: selective inhibition of aromatase. J Med Chem 28:200–204.

    PubMed  CAS  Google Scholar 

  82. Haynes BP, Jarman M, Dowsett M, Mehta A, Lonning PE, Griggs LJ, Powles T, Stein R, Coombes RC. 1991. Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer. Cancer Chemother Pharmacol 27:367–372.

    PubMed  CAS  Google Scholar 

  83. Plourde PV, Dyroff M, Dowsett M, Demers L, Yates R, Webster A. 1995. ARIMIDEX: a new oral, once-a-day aromatase inhibitor (review). J Steroid Biochem Mol Biol 53:175–179.

    PubMed  CAS  Google Scholar 

  84. Jonat W, Howell A, Blomqvist C, Eiermann W, Winblad G, Tyrrell C, Mauriac L, Roche H, Lundgren S, Hellmund R, Azab M. 1996. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Armidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32A:404–412.

    PubMed  CAS  Google Scholar 

  85. Dowsett M. 1991. Inhibitors of steroidogenic enzymes for the treatment of breast cancer (review). J Steroid Biochem Mol Biol 39:805–809.

    PubMed  CAS  Google Scholar 

  86. Williams CJ, Barley VL, Blackledge GR, Rowland CG, Tyrrell CJ. 1993. Multicentre cross over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer. Br J Cancer 68:1210–1215.

    PubMed  CAS  Google Scholar 

  87. Brodie AM, Wing LY, Goss P, Dowsett M, Coombes RC. 1986. Aromatase inhibitors and the treatment of breast cancer. J Steroid Biochem 24:91–97.

    PubMed  CAS  Google Scholar 

  88. Pickles T, Perry L, Murray P, Plowman P. 1990. 4-hydroxyandrostenedione - further clinical and extended endocrine observations. Br J Cancer 62:309–313.

    PubMed  CAS  Google Scholar 

  89. Stein RC, Dowsett M, Hedley A, Davenport J, Gazet JC, Ford HT. 1990. Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione. Cancer Chemother Pharmacol 26:75–78.

    PubMed  CAS  Google Scholar 

  90. Hoffken K, Jonat W, Possinger K, et al. 1990. Aromatase inhibition with 4hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study. J Clin Oncol 8:875–880.

    PubMed  CAS  Google Scholar 

  91. Possinger K, Jonat W, Hoffken K. 1994. Formestane in the treatment of advanced postmenopausal breast cancer. Ann Oncol 5 (Suppl 7):S7–S10.

    PubMed  Google Scholar 

  92. Zilembo N, Bajetta E, Noberasco C, Buzzoni R, Vicario G, Bono A, Laffranchi A, Biasi G, Dolci S, Bichisao E. 1995. Formestane: an effective first-line endocrine treatment for advanced breast cancer. J Cancer Res Clin Oncol 121:378–382.

    PubMed  CAS  Google Scholar 

  93. Perez Carrion R, Alberola Candel V, Calabresi F, et al. 1994. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol 5 (Suppl 7):S19–S24.

    PubMed  Google Scholar 

  94. Coombes RC, Goss PE, Dowsett M, Hutchinson G, Cunningham D, Jarman M. 1987. 4Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer. Steroids 50:245–252.

    PubMed  CAS  Google Scholar 

  95. Zilembo N, Noberasco C, Bajetta E, et al. 1995. Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. Br J Cancer 72:1007–1012.

    PubMed  CAS  Google Scholar 

  96. Lipton A, Harvey HA, Demers LM, Hanagan JR, Mulagha MT, Kochak GM, Sanders SI, Santen RJ. 1990. A phase I trial of CGS 16949A. A new aromatase inhibitor. Cancer 65:1279–1285.

    PubMed  CAS  Google Scholar 

  97. Demers LM, Lipton A, Harvey HA, Hanagan J, Mulagha M, Santen RJ. 1993. The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer. J Steroid Biochem Mol Biol 44:683–685.

    PubMed  CAS  Google Scholar 

  98. Santen RJ, Demers LM, Lynch J, et al. 1991. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor. J Clin Endocrinol Metab 73:99–106.

    PubMed  CAS  Google Scholar 

  99. Raats JI, Falkson G, Falkson HC. 1992. A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer. J Clin Oncol 10:111–116.

    PubMed  CAS  Google Scholar 

  100. Bhatnagar AS, Hausler A, Schieweck K, Lang M, Bowman R. 1990. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor (review). J Steroid Biochem Mol Biol 37:1021–1027.

    PubMed  CAS  Google Scholar 

  101. Perez N, Borja J. 1992. Aromatase inhibitors: clinical pharmacology and therapeutic implications in breast cancer. J Int Med Res 20:303–312.

    PubMed  CAS  Google Scholar 

  102. Lipton A, Demers LM, Harvey HA, Kambic KB, Grossberg H, Brady C, Adlercruetz H, Trunet PF, Santen RJ. 1995. Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer 75:2132–2138.

    PubMed  CAS  Google Scholar 

  103. Iveson TJ, Smith IE, Ahern J, Smithers DA, Trunet PF, Dowsett M. 1993. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res 53:266–270.

    PubMed  CAS  Google Scholar 

  104. Dowsett M, Johnston SRD, Doody D, et al. 1994. The clinical and endocrine effects of the oral aromatase inhibitor vorozole in human breast cancer (abstract). Proc ASCO 13:71.

    Google Scholar 

  105. Goss PE, Clark R, Ambus U, et al. 1994. Phase II study of vorozole (R 83842) a new aromatase inhibitor in postmenopausal women with advanced breast cancer (abstract). Proc ASCO 13:88.

    Google Scholar 

  106. Vinholes J, Paridains R, Piccart MJ, et al. 1994. An EORTC breast group phase II study of vorozole (R 83842), a new aromatase inhibitor in advanced breast cancer (abstract). Proc ASCO 13:105.

    Google Scholar 

  107. Goldenberg IS, Waters N, Ravdin RS, Ansfield FJ, Segaloff A. 1973. Androgenic therapy for advanced breast cancer in women. A report of the Cooperative Breast Cancer Group. JAMA 223:1267–1268.

    PubMed  CAS  Google Scholar 

  108. Manni A, Arafah BM, Pearson Oh. 1981. Androgen-induced remissions after antiestrogen and hypophysectomy in stage IV breast cancer. Cancer 48:2507–2509.

    PubMed  CAS  Google Scholar 

  109. Peters TG, Lewis JD, Wilkinson EJ, Fuhrman TM. 1977. Danazol therapy in hormone-sensitive mammary carcinoma. Cancer 40:2797–2800.

    PubMed  CAS  Google Scholar 

  110. Coombes RC, Dearnaley D, Humphreys J, Gazet JC, Ford HT, Nash AG, Mashiter K, Powles TJ. 1980. Danazol treatment of advanced breast cancer. Cancer Treat Rep 64:1073–1076.

    PubMed  CAS  Google Scholar 

  111. Coombes RC, Perez D, Gazet JC, Ford HT, Powles TJ. 1983. Danazol treatment for advanced breast cancer. Cancer Chemother Pharmacol 10:194–195.

    PubMed  CAS  Google Scholar 

  112. Brodovsky HS, Holroyde CP, Laucius JF, Dugery C, Serbin J. 1987. Danazol in the treatment of women with metastatic breast cancer. Cancer Treat Rep 71:875–876.

    PubMed  CAS  Google Scholar 

  113. Pronzato P, Amoroso D, Ardizzoni A, Bertelli G, Conte PF, Michelotti A, Rosso R. 1987. A phase II study of danazol in metastatic breast cancer. Am J Clin Oncol 10:407–409.

    PubMed  CAS  Google Scholar 

  114. Huggins C, Yang NC. 1962. Induction and extinction of mammary cancer. Science 137:257–262.

    PubMed  CAS  Google Scholar 

  115. Petru E, Schmahl D. 1987. On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide. in advanced breast cancer. Klin Wochen 65:959–966.

    CAS  Google Scholar 

  116. Liber J, Rose C, Salimtschik M, Mouridsen HT. 1981. Treatment of advanced breast cancer with progestins. Acta Obstet Gynecol Scand - Suppl 101:39–46.

    Google Scholar 

  117. Haller DG, Glick JH. 1986. Progestational agents in advanced breast cancer: an overview. Semin Oncol 13:2–8.

    PubMed  CAS  Google Scholar 

  118. Pannuti F, Martoni A, Piana E, et al. Progestins in breast cancer. In Pannuti F, ed. Hormonotherapy: Results and Perspectives. Pavia (Italy): Edizioni, pp. 207–222.

    Google Scholar 

  119. Parazzini F, Colli E, Scatigna M, Tozzi L. 1993. Treatment with tamoxifen and progestins for metastatic breast cancer in postmenopausal women: a quantitative review of published randomized clinical trials (review). Oncology 50:483–489.

    PubMed  CAS  Google Scholar 

  120. Sedlacek SM, Horwitz KB. 1991. The role of progestins and progesterone receptors in the treatment of breast cancer. Steroids 44:467–483.

    Google Scholar 

  121. Pannuti F, Martoni A, Di Marco AR, et al. 1979. Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancer. Eur J Cancer 15:593–601.

    PubMed  CAS  Google Scholar 

  122. Della Cuna GR, Calciati A, Strada MRB, Bumma C, Campio L. 1978. High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation. Tumori 64:143–149.

    Google Scholar 

  123. Cortes Funes H, Madrigal PL, Perez Mangas G, et al. 1983. Medroxyprogesterone acetate at two different doses for the treatment of advanced breast cancer. In Campio L, Robustelli Della Cuna G, Taylor RW, eds. Role of Medroxyprogesterone in Endocrine Related Tumors, 2nd ed. New York: Raven Press, pp. 77–83.

    Google Scholar 

  124. Cavalli F, Goldhirsch A, Jungi F, Martz G, Mermillod B, Alberto P. 1984. Randomized trial of low-versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer. J Clin Oncol 2:414–419.

    CAS  Google Scholar 

  125. Gallagher CJ, Cairnduff F, Smith IE. 1987. High dose versus low dose medroxyprogesterone acetate: a randomized trial in advanced breast cancer. Eur J Cancer Clin Oncol 23:1895–1900.

    PubMed  CAS  Google Scholar 

  126. Sedlacek SM. 1988. An overview of megestrol acetate for the treatment of advanced breast cancer. Semin Oncol 15:3–13.

    PubMed  CAS  Google Scholar 

  127. Brufman G, Isacson R, Haim N, Gez E, Sulkes A. 1994. Megestrol acetate in advanced breast carcinoma after failure to tamoxifen and/or aminoglutethimide. Oncology 51:258–261.

    PubMed  CAS  Google Scholar 

  128. Muss HB, Case LD, Capizzi RL, et al. 1990. High-versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association. J Clin Oncol 8:1797–1805.

    PubMed  CAS  Google Scholar 

  129. Muss HB, Case LD, Atkins JN, et al. 1994. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study (see comments). J Clin Oncol 12:1630–1638.

    PubMed  CAS  Google Scholar 

  130. DeSombre ER, Johnson ES, White WF. 1976. Regression of rat mammary tumors effected by a gonadoliberin analog. Cancer Res 36:3830–3833.

    Google Scholar 

  131. Klijn JG. 1992. LH-RH agonists in the treatment of metastatic breast cancer: ten years’ experience (review). Recent Results Cancer Res 124:75–90.

    PubMed  CAS  Google Scholar 

  132. Belchetz PE, Plant TM, Nakai Y, Keogh EJ, Knobil E. 1978. Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science 202:631–633.

    PubMed  CAS  Google Scholar 

  133. Conn PM, Crowley WF Jr. 1991. Gonadotropin-releasing hormone and its analogues (see comments) (review). N Engl J Med 324:93–103.

    PubMed  CAS  Google Scholar 

  134. Harris AL, Carmichael J, Cantwell BM, Dowsett M. 1989. Zolodex: endocrine and therapeutic effects in post-menopausal breast cancer. Br J Cancer 59:97–99.

    PubMed  CAS  Google Scholar 

  135. Eidne KA, Flanagan CA, Millar RP. 1985. Gonadotropin-releasing hormone binding sites in human breast carcinoma. Science 229:989–991.

    PubMed  CAS  Google Scholar 

  136. Miller WR, Scott WN, Morris R, Fraser HM, Sharpe RM. 1985. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 313:231–233.

    PubMed  CAS  Google Scholar 

  137. Bajetta E, Zilembo N, Buzzoni R, Celio L, Zampino MG, Colleoni M, Oriana S, Attili A, Sacchini V, Martinetti A. 1994. Goserelin in premenopausal advanced breast cancer: clinical and endocrine evaluation of responsive patients. Oncology 51:262–269.

    PubMed  CAS  Google Scholar 

  138. Kaufmann M, Jonat W, Kleeberg U, et al. 1989. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group. J Clin Oncol 7:1113–1119.

    PubMed  CAS  Google Scholar 

  139. Hardy JR, Powles TJ, Judson IR, Sinnett HD, Ashley SE, Coombes RC, Ellin CL. 1990. Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer. Eur J Cancer 26:824–827.

    PubMed  CAS  Google Scholar 

  140. Mouridsen HT, Salimtschik M, Dombernowsky P, Gelshoj K, Palshof T, Daehnfeldt JL, Rose C. 1980. Therapeutic effect of tamoxifen versus combined tamoxifen and dicthylstilboestrol in advanced breast cancer in postmenopausal women. Eur J Cancer Suppl 1: 107–110.

    Google Scholar 

  141. Ingle JN, Twito DI, Schaid DJ, et al. 1988. Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer. J Clin Oncol 6:825–831.

    PubMed  CAS  Google Scholar 

  142. Ingle JN, Green SJ, Ahmann DL, Long HJ, Edmonson JH, Rubin J, Chang MN, Creagan ET. 1986. Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. J Clin Oncol 4:958–964.

    PubMed  CAS  Google Scholar 

  143. Bezwoda WR, Meyer K. 1990. Effect of alpha-interferon, 17 beta-estradiol, and tamoxifen on estrogen receptor concentration and cell cycle kinetics of MCF 7 cells. Cancer Res 50:5387–5391.

    PubMed  CAS  Google Scholar 

  144. Seymour L, Bezwoda WR. 1993. Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulators. Br J Cancer 68:352–356.

    PubMed  CAS  Google Scholar 

  145. Cobleigh MA, Dowlatshahi K, Deutsch TA, et al. 1993. Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. J Clin Oncol 11:474–477.

    PubMed  CAS  Google Scholar 

  146. Vink-van Wijngaarden T, Pols HA, Buurman CJ, van den Bernd GJ, Dorssers LC, Birkenhager JC, van Leeuwen JP. 1994. Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen. Cancer Res 54:5711–5717.

    PubMed  CAS  Google Scholar 

  147. Candi E, Melino G, De Laurenzi V, Piacentini M, Guerrieri P, Spinedi A, Knight RA. 1995. Tamoxifen and somatostatin affect tumours by inducing apoptosis. Cancer Lett 96:141–145.

    PubMed  CAS  Google Scholar 

  148. Lissoni P, Barni S, Meregalli S, Fossati V, Cazzaniga M, Esposti D, Tancini G. 1995. Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer 71:854–856.

    PubMed  CAS  Google Scholar 

  149. Binder SC, Flynn WJ, Pass LM. 1977. Endocrine ablative therapy of metastatic breast cancer. CA 27:1–9.

    Google Scholar 

Download references

Authors
  1. Gretchen G. Kimmick
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hyman B. Muss
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA

    Kenneth A. Foon M.D.

  2. College of Medicine, Vermont Cancer Center, University of Vermont, Burlington, Vermont, USA

    Hyman B. Muss M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media New York

About this chapter

Cite this chapter

Kimmick, G.G., Muss, H.B. (1998). Endocrine therapy in metastatic breast cancer. In: Foon, K.A., Muss, H.B. (eds) Biological and Hormonal Therapies of Cancer. Cancer Treatment and Research, vol 94. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-6189-7_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-6189-7_13

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7837-2

  • Online ISBN: 978-1-4615-6189-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation